leader image

Monica D’Arcy, MS, PhD

Instructor
Center for Pharmacoepidemiology and Treatment Science (PETS)
Core Faculty
Institute for Health, Health Care Policy, and Aging Research

Monica D’Arcy is a cancer and pharmacoepidemiologist. She received her undergraduate degrees in mathematics and computer science engineering from the University of Pennsylvania, her MS in epidemiology from Temple University and her PhD from the University of North Carolina in cancer and pharmacoepidemiology. She also completed a postdoctoral fellowship in cancer epidemiology at the National Cancer Institute in the Division of Cancer Epidemiology and Genetics (2022). Prior to initiating her doctoral degree, she worked for almost a decade as a software developer and bioinformatics specialist in both industry and at the Children’s Hospital of Philadelphia. She has extensive experience using several types of big data for epidemiologic cancer studies including gene expression, Medicare claims, the Clinical Practice Datalink and SEER-Medicare. A common theme underlying her research is the use of diverse data sources and novel strategies to reduce the burden of cancer.

Research Profile

Pharmacoepidemiology, cancer (lung, colorectal, breast, immune-related) etiology and survival, innovative use of data for epidemiologic research, social factors and cancer outcomes, precision medicine

Selected Publications 

  1. D’Arcy ME, Beachler DC, Pfeiffer RM, Curtis JR, Mariette X, Seror R, Mahale P, Rivera DR, Yanik EL, Engels EA.; Tumor Necrosis Factor Inhibitors and the Risk of Cancer among Older Americans with Rheumatoid Arthritis; Cancer Epidemiol Biomarkers Prev. 30(11):2059-2067, 2021
  2. Jayaraman P, Mosbruger T, Hu T, Tairis NG, Wu C, Clark PM, D’Arcy M, Ferriola D, Mackiewicz K, Gai X, Monos D, Sarmady M.; AnthOligo: automating the design of oligonucleotides for capture/enrichment technologies; Bioinformatics, 36(15):4353-4356, 2020
  3. D’Arcy ME, Castenson D, Lynch CF, Kahn AR, Morton LM, Shiels MS, Pfeiffer RM, Engels EA.; Risk of Rare Cancers Among Solid Organ Transplant Recipients; J Natl Cancer Inst.,113(2):199-207, 2021
  4. D’Arcy ME, Pfeiffer RM, Rivera DR, Hess GP, Cahoon EK, Arron ST, Brownell I, Cowen EW, Israni AK, Triplette MA, Yanik EL, Engels EA.; Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States; JAMA Dermatology,156(7):772-779, 2020
  5. D’Arcy ME, Coghill AE, Lynch CF, Koch LA, Li J, Pawlish KS, Morris CR, Rao C, Engels EA.; Survival after a cancer diagnosis among solid organ transplant recipients in the United States; Cancer, 125(6):933-942, 2019
  6. D’Arcy M, Stürmer T, Lund JL.; The importance and implications of comparator selection in pharmacoepidemiologic research; Curr Epidemiol Rep, 5(3):272-283, 2018